Why the study?
Does the presence of an apical aneurysm worsen myocardial work parameters in patients with apical hypertrophic cardiomyopathy?
Does the presence of an apical aneurysm worsen myocardial work parameters in patients with apical hypertrophic cardiomyopathy?
Answers are grounded in this paper and cite their sources.
In patients with apical hypertrophic cardiomyopathy, the presence of an apical aneurysm is associated with worse myocardial work efficiency and greater wasted work, suggesting impaired myocardial metabolic health.
Mihos and coworkers [1] present an interesting report on the impact of apical aneurysm in patients with apical hypertrophic cardiomyopathy (ApHCM). They reference the literature that shows it occurs in 10%–15% of patients with ApHCM and that its presence confers a 3-fold increase in HCM-related death or life-saving aborted HCM-related events, and that it is considered a marker of increased risk of sudden death [2, 3]. They identified 98 ApHCM patients retrospectively of whom 9 (9%) had an apical aneurysm (ApAn+) and 89 (91%) did not (ApAn−). Of the 9 ApAn+ patients, there were 6 small (< 2 cm) and 3 moderate-sized (2–4 cm) aneurysms. There was a slight, but not statistically significant, difference between the NYHA functional class of 1.7 for the ApAn+ vs. 0.9 for the ApAn− group (p = 0.07). There was no difference in the two groups of ApAn− and ApAn+ with respect to any other demographic including age years (64 vs. 64), F gender % (44 vs. 67) EF% (67 vs. 65), septal wall thickness mm (15 vs. 15), apical wall thickness mm (19 vs. 18), obstructive physiology (8% vs. 11%), systolic anterior motion (12% vs. 0%), or moderate to severe mitral regurgitation (8% vs. 11%). They followed up the patients for a median time of 3.9 years. There were 4 (4%) cardiovascular mortalities, 2 (2%) sudden cardiac deaths, and 14 (14%) patients had at least one hospitalization for heart failure. There were no between-group differences noted in clinical outcomes. The nondifference in outcomes may reflect the small sample size or perhaps better understanding and management of patients with ApAn than in the past. Despite the similarities between the two groups with respect to echocardiographic and clinical aspects, they did, however, find a difference between the groups in some novel echocardiographic parameters that are not a usual part of the echocardiographer's armamentarium. While most of us are familiar with global longitudinal strain (GLS), they also looked at the concepts of “global work efficiency” (GWE), and “global wasted work” (GWW). While GLS provides better insight into LV systolic function than EF, it is nevertheless affected by changes in afterload. Myocardial work (MW) integrates afterload (arm blood pressure) with GLS to create an LV pressure-strain loop [3, 4]. They calculated four several work parameters–global work index, global constructive work, global wasted work, and global work efficiency. They discovered that the ApAn+ patients had greater GWW, and worse GWE than ApAn− patients but there was no significant difference in GLS. These differences suggest that patients with ApAn+ may have worse “myocardial metabolic health” than ApAn− patients with possibly greater fibrosis. The question is which is the chicken and which is the egg? Is the underlying abnormality of GWE and GWW a cause of the aneurysm, or a consequence? It seems hard to believe that such a small area of the heart could cause a global abnormality. So maybe the underlying global work differences provide an insight into why certain ApHCM patients develop an aneurysm and others do not. The authors mention several possibilities as to why aneurysms develop in these patients including repetitive myocardial ischemic insult and delayed and persistent systolic contraction into early diastole resulting in transmural apical scarring [5-7]. Apical aneurysms are also associated with subarachnoid hemorrhage [8] and Takotsubo cardiomyopathy [9] and are thought to be due to excess catecholamine which is also presumed to cause the “suicide ventricle” seen in a variety of clinical situations. Apical left ventricular cavity obliteration is also not confined to hypertrophic cardiomyopathy [10] but rarely, in my experience, is associated with apical aneurysms. This suggests that the apical aneurysms seen in ApHCM are related more to the abnormal myocardial architecture than the hypercontractility per se or are due to the combination rather than one element alone. Therefore, though this is a small study, it provides not only an interesting insight into the apical aneurysm that can occur with ApHCM but also a possible insight into noncoronary apical aneurysms that occur in other conditions. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
No takes yet. Share an insight, caveat, or question.
Charles Pollick (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: